<?xml version="1.0" encoding="ISO-8859-1"?>
<entity-relation-data lastUpdate="2023-03-27 16:07:23" record="1371" source="Espacenet">
	<entities>
		<entity ref="Patent1371" type="Patent">
			<semanticIdentifier>brcris::39d59e65de4c4f865f65cfa5fbaea459</semanticIdentifier>
			<semanticIdentifier>docdb::BR102019004425A2</semanticIdentifier>
			<semanticIdentifier>epodoc::BR102019004425</semanticIdentifier>
			<semanticIdentifier>docdb::BR102019004425A</semanticIdentifier>
			<semanticIdentifier>epodoc::BR20191004425</semanticIdentifier>
			<semanticIdentifier>original::102019004425</semanticIdentifier>
			<field name="urlEspacenet" value="https://worldwide.espacenet.com/patent/search?q=102019004425"/>
			<field name="identifier.lattes" value="4759006674013596"/>
			<field name="identifier.espacenet" value="102019004425"/>
			<field name="kindCode" value="A2"/>
			<field name="title.espacenet" value="atividade antimalárica dos compostos anisodamina e erypoegin"/>
			<field name="title.lattes" value="Atividade Antimalárica dos Compostos Anisodamina e Erypoegin"/>
			<field name="depositDate" value="2019-03-07"/>
			<field name="publicationDate" value="2020-09-29"/>
			<field name="countryCode" value="BR"/>
			<field name="inventor" value="ALEX GUTTERRES TARANTO"/>
			<field name="inventor" value="AMANDA LUISA DA FONSECA"/>
			<field name="inventor" value="DAVID BACELAR COSTA JUNIOR"/>
			<field name="inventor" value="FERNANDO DE PILLA VAROTTI"/>
			<field name="inventor" value="FRANCO HENRIQUE ANDRADE LEITE"/>
			<field name="applicant" value="FUNDACAO DE AMPARO A PESQUISA DO ESTADO DE MINAS GERAIS"/>
			<field name="applicant" value="UNIVERSIDADE ESTADUAL DE FEIRA DE SANTANA"/>
			<field name="applicant" value="UNIVERSIDADE FEDERAL DE SAO JOAO DEL REI"/>
			<field name="classification.ipc">
				<field name="sequence" value="1"/>
				<field name="text" value="A61K31/37AI"/>
				<field name="section" value="A"/>
				<field name="class" value="61"/>
				<field name="subclass" value="K"/>
				<field name="group" value="31"/>
				<field name="subgroup" value="37AI"/>
			</field>
			<field name="classification.ipc">
				<field name="sequence" value="2"/>
				<field name="text" value="A61K31/46AI"/>
				<field name="section" value="A"/>
				<field name="class" value="61"/>
				<field name="subclass" value="K"/>
				<field name="group" value="31"/>
				<field name="subgroup" value="46AI"/>
			</field>
			<field name="classification.ipc">
				<field name="sequence" value="3"/>
				<field name="text" value="A61P33/06AI"/>
				<field name="section" value="A"/>
				<field name="class" value="61"/>
				<field name="subclass" value="P"/>
				<field name="group" value="33"/>
				<field name="subgroup" value="06AI"/>
			</field>
			<field name="classification.ipc">
				<field name="sequence" value="4"/>
				<field name="text" value="C07D311/16AI"/>
				<field name="section" value="C"/>
				<field name="class" value="07"/>
				<field name="subclass" value="D"/>
				<field name="group" value="311"/>
				<field name="subgroup" value="16AI"/>
			</field>
			<field name="classification.ipc">
				<field name="sequence" value="5"/>
				<field name="text" value="C07D451/10AI"/>
				<field name="section" value="C"/>
				<field name="class" value="07"/>
				<field name="subclass" value="D"/>
				<field name="group" value="451"/>
				<field name="subgroup" value="10AI"/>
			</field>
			<field name="abstract.espacenet" value="atividade antimalárica dos compostos anisodamina e erypoegin a malária é uma doença parasitária que acomete grande parte da população mundial. na ausência de uma vacina eficaz, seu tratamento depende do uso de quimioterápicos e a necessidade de novos tratamentos é reforçada pela crescente resistência identificada aos antimaláricos atuais. assim, o presente estudo teve como objetivo avaliar a atividade antimalárica in vitro dos compostos contra a cepa p. falciparum (w2). para tanto os compostos (s)-3- hidroxy-2-phenyl-propionic acid (1r,3s,5r,6s)-6-hidroxy-8-methyl-8-aza-bic e 7- (2-(4-methoxy-phenyl)-2-oxo-ethoxy)-3,4,8-trimethyl-chromen2-on foram testados utilizando o teste tradicional. além disso, foi realizado o ensaio de citotoxicidade utilizando a linhagem celular wi-26va4 pelo teste de mtt para verificação da viabilidade celular. experimentalmente verificou-se que os compostos não apresentam citotoxicidade, que o composto s)-3- hidroxy-2-phenyl-propionic acid (1r,3s,5r,6s)-6-hidroxy-8-methyl-8-aza-bic possui menor valor de ic50. desta forma, os resultados sugerem que estes compostos podem ser usados como antimaláricos. a presente invenção demonstra os produtos (compostos) (s)-3-hidroxy-2-phenyl-propionic acid (1r,3s,5r,6s)-6-hidroxy-8-methyl-8-aza-bic e 7-(2-(4-methoxyphenyl)-2-oxo-ethoxy)-3,4,8-trimethyl-chromen-2-o como agentes antimaláricos."/>
			<field name="originatesFrom" value="73013985"/>
			<field name="alternateIdentifier">
				<field name="status" value="Publication"/>
				<field name="format" value="docdb"/>
				<field name="country" value="BR"/>
				<field name="number" value="102019004425"/>
				<field name="kind" value="A2"/>
			</field>
			<field name="alternateIdentifier">
				<field name="status" value="Publication"/>
				<field name="format" value="epodoc"/>
				<field name="country" value="BR"/>
				<field name="number" value="BR102019004425"/>
				<field name="kind" value=""/>
			</field>
			<field name="alternateIdentifier">
				<field name="status" value="Application"/>
				<field name="format" value="docdb"/>
				<field name="country" value="BR"/>
				<field name="number" value="102019004425"/>
				<field name="kind" value="A"/>
			</field>
			<field name="alternateIdentifier">
				<field name="status" value="Application"/>
				<field name="format" value="epodoc"/>
				<field name="country" value="BR"/>
				<field name="number" value="BR20191004425"/>
				<field name="kind" value=""/>
			</field>
			<field name="alternateIdentifier">
				<field name="status" value="Application"/>
				<field name="format" value="original"/>
				<field name="country" value=""/>
				<field name="number" value="102019004425"/>
				<field name="kind" value=""/>
			</field>
		</entity>
		<entity ref="Person1027" type="Person">
			<semanticIdentifier>lattes::4759006674013596</semanticIdentifier>
			<field name="identifier.lattes" value="4759006674013596"/>
			<field name="name" value="Alex Gutterres Taranto"/>
		</entity>
		<entity ref="OrgUnit812" type="OrgUnit">
			<semanticIdentifier>brcris::3e60fe4cbc4ad65afa2393d0a704c5ea</semanticIdentifier>
			<field name="name" value="FUNDACAO DE AMPARO A PESQUISA DO ESTADO DE MINAS GERAIS"/>
		</entity>
		<entity ref="OrgUnit813" type="OrgUnit">
			<semanticIdentifier>brcris::a4b576e8ee4977c8471b98f4515e9d1e</semanticIdentifier>
			<field name="name" value="UNIVERSIDADE ESTADUAL DE FEIRA DE SANTANA"/>
		</entity>
		<entity ref="OrgUnit814" type="OrgUnit">
			<semanticIdentifier>brcris::2afe863ef6ddd4c44a77f737f4b0cc24</semanticIdentifier>
			<field name="name" value="UNIVERSIDADE FEDERAL DE SAO JOAO DEL REI"/>
		</entity>
	</entities>
	<relations>
		<relation fromEntityRef="Patent1371" toEntityRef="Person1027" type="Inventor"/>
		<relation fromEntityRef="Patent1371" toEntityRef="OrgUnit812" type="Applicant"/>
		<relation fromEntityRef="Patent1371" toEntityRef="OrgUnit813" type="Applicant"/>
		<relation fromEntityRef="Patent1371" toEntityRef="OrgUnit814" type="Applicant"/>
	</relations>
</entity-relation-data>
